A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye

Phase 3

Completed

• Conditions: Dry Eye Syndromes
• Interventions: Drug: Omega 3; Drug: Optive Advanced; Drug: Optive

• Registration Number: NCT02871440
• Lead Sponsor: The University of New South Wales

Brief Summary

Omega 3 (OM3) Tear is a new unit dose emulsion, containing flaxseed/castor oil, which is being developed by Allergan. It is desirable to understand the effect that this new emulsion has on tear film evaporation and tear lipid profile via interferometry, in patients with evaporative dry eye (EDE) and those without (non-EDE). It would also be valuable to evaluate the retention time of the lipid components of the new emulsion via tear collection and analysis in EDE and non-EDE patients

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-15
• Study First Submitted QC: 2016-08-17
• Study First Posted: 2016-08-18
• Study Start: 2016-09-19
• Primary Completion: 2017-09-18
• Study Completion: 2017-09-18
• Results First Submitted: 2019-08-30
• Status Verified: 2020-05
• Results First Submitted QC: 2020-05-11
• Last Update Submitted: 2020-05-11
• Results First Posted: 2020-05-12
• Last Update Posted: 2020-05-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
• Over 18 years of age;
• Not wearing contact lenses in the past 3 months before enrolling
• Willing to use eye drops and comply with the study visit schedule as directed by the Investigator;
• Habitual (corrected or uncorrected) visual acuity of 6/9.5 or better in each eye;
• At the Screening visit (Day -14), patients must have Ocular Surface Disease Index (OSDI) score >18 (0 to 100 scale). At Baseline (Day 1) visits, patients must have OSDI score > 12 to continue in the study.
• TBUT≤10sec in at least 1 eye at Screening visit and Baseline visit
• Corneal sodium fluorescein staining score ≥ 1 and <4 (Oxford scheme) at Screening and Baseline visit.

Exclusion Criteria

• Schirmer test (with anesthesia) ≤ 2 mm in either eye at Screening
• Patients who are currently using topical ocular medication or have used topical ocular medication within 2 weeks of the Screening visit. Patients who are being treated bilaterally with a marketed artificial tear for dry eye can be considered, provided they discontinue use at the Screening visit;
• Any active anterior segment disease excluding blepharitis;
• Any systemic disease that may affect ocular health e.g. Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis and systemic lupus erythematosus;
• History of epilepsy or migraines exacerbated by flashing, strobe-like lights;
• Rigid or soft contact lens wearer, including orthokeratology;
• History of eye surgery within 6 months prior to enrolment in the study;
• Previous corneal refractive surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Eye drop 1	Omega 3	Omega 3
Eye drop 2	Optive Advanced	Optive Advanced
Eye drop 3	Optive	Optive

Primary Outcome Measures

Name	Time	Method
Tear Evaporation Rate	Assessed at 4 weeks	Measured using a Vapometer (g/m\^2\*h)

Secondary Outcome Measures

Name	Time	Method
Tear Break-up Time	Assessed at 4 weeks	Measured with fluorescein dye (seconds)
Subjective Ocular Comfort	Assessed at 4 weeks	Measured using visual analogue scales (0-100); 0 indicates no/less symptoms and 100 indicates maximum/worse symptoms.